ReviewExpert opinion on drug discovery2012
Third-generation sequencing techniques and applications to drug discovery.
Review in Expert opinion on drug discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Decreased expression of ribonucleotide reductase M2 accelerates ovarian aging by suppressing cell proliferation and inducing DNA damage in mouse theca-interstitial cells.Journal of ovarian research · 2026Article
- Next generation sequencing and beyond: a review of genomic sequencing methods.Functional & integrative genomics · 2025Article
- Leveraging long-read sequencing technologies for pharmacogenomic testing: applications, analytical strategies, challenges, and future perspectives.Frontiers in genetics · 2025Review
- Human pangenome: far-reaching implications in precision medicine.Frontiers of medicine · 2024Article
- Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies.International journal of molecular sciences · 2023Review
- Single-Molecule Real-Time Sequencing of Full-Length Transcriptome and Identification of Genes Related to Male Development inPlants (Basel, Switzerland) · 2022Article
- InnovativeFrontiers in genetics · 2022Review
- Third-Generation Sequencing: The Spearhead towards the Radical Transformation of Modern Genomics.Life (Basel, Switzerland) · 2021Review
- Functional Annotation of a Full-Length Transcriptome and Identification of Genes Associated with Flower Development inPlants (Basel, Switzerland) · 2021Article
- Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma.Medicine · 2020Article
- High-Throughput Transcriptome Profiling in Drug and Biomarker Discovery.Frontiers in genetics · 2020Review
- LONG-NONCODING RNAs in gastroesophageal cancers.Non-coding RNA research · 2018Review
- Managing risks in drug discovery: reproducibility of published findings.Naunyn-Schmiedeberg's archives of pharmacology · 2016Review
- Plant exomics: concepts, applications and methodologies in crop improvement.Plant signaling & behavior · 2015Review
- Plant pathogen nanodiagnostic techniques: forthcoming changes?Biotechnology, biotechnological equipment · 2014Article
- DNA fingerprinting in zoology: past, present, future.Investigative genetics · 2014Article
- Biases in small RNA deep sequencing data.Nucleic acids research · 2014Review
- Genes, behavior and next-generation RNA sequencing.Genes, brain, and behavior · 2013Review
- Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective.Nature reviews. Drug discovery · 2013Review
- Targeted transcript profiling by sequencing.Scientific reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
introductionThere is an immediate need for functional and molecular studies to decipher differences between disease and 'normal' settings to identify large quantities of validated targets with the highest therapeutic utilities. Furthermore, drug mechanism of action and biomarkers to predict drug efficacy and safety need to be identified for effective design of clinical trials, decreasing attrition rates, regulatory agency approval process and drug repositioning. By expanding the power of genetics and pharmacogenetics studies, next-generation nucleic acid sequencing technologies have started to play an important role in all stages of drug discovery. AREAS COVERED: This article reviews the first- and second-generation sequencing technologies (SGSTs) and challenges they pose to biomedicine. The article then focuses on the emerging third-generation sequencing technologies (TGSTs), their technological foundations and potential contributions to drug discovery. EXPERT OPINION: Despite the scientific and commercial success of SGSTs, the goal of rapid, comprehensive and unbiased sequencing of nucleic acids has not been achieved. TGSTs promise to increase sequencing throughput and read lengths, decrease costs, run times and error rates, eliminate biases inherent in SGSTs and offer capabilities beyond nucleic acid sequencing. Such changes will have positive impact on all sequencing applications to drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.